Acquisitions - HilleVax Acquisition - Total purchase consideration (Details) - HilleVax - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | |
|---|---|---|---|
Sep. 17, 2025 |
Sep. 30, 2025 |
Sep. 30, 2025 |
|
| Asset acquisition | |||
| Closing cash payment | $ 98,968 | ||
| CVR consideration adjustment | 5,673 | $ 5,700 | $ 5,700 |
| Transaction costs | 708 | ||
| Total purchase consideration | $ 105,349 |
| X | ||||||||||
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of transaction cost incurred as part of consideration transferred in asset acquisition. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Asset Acquisition, Contingent Value Rights, Consideration Adjustment No definition available.
|
| X | ||||||||||
- Details
|